

Joan T Merrill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4556753/publications.pdf>

Version: 2024-02-01

167
papers

18,712
citations

50566

48
h-index

14012

133
g-index

175
all docs

175
docs citations

175
times ranked

14657
citing authors

#	ARTICLE	IF	CITATIONS
1	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.5	42
2	Reply. <i>Arthritis and Rheumatology</i> , 2022, 74, 1093-1093.	2.9	0
3	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.5	9
4	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 951-961.	0.5	38
5	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 1822-1828.	1.5	9
6	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 962-969.	0.5	15
7	Biological impact of iberdomide in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1136-1142.	0.5	13
8	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	1.5	13
9	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	1.5	22
10	Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1562-1567.	0.6	17
11	Challenges of systemic lupus clinical trials. , 2021, , 673-682.		0
12	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5379-5389.	0.9	11
13	SARS-CoV-2 vaccines in patients with SLE. <i>Lupus Science and Medicine</i> , 2021, 8, e000479.	1.1	30
14	Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 1254-1263.	0.8	36
15	Anti-beta 2 glycoprotein I IgA in the SLICC classification 2 criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	0.8	3
16	Immune Response to <i>Enterococcus gallinarum</i> in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. <i>Frontiers in Immunology</i> , 2021, 12, 635072.	2.2	15
17	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	2.9	7
18	What Did Not Work: The Drug or the Trial?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1773-1775.	2.9	6

#	ARTICLE	IF	CITATIONS
19	Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100117.	2.0	15
20	1124€...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
21	1107€...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
22	801€...Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
23	1704€...Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
24	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	2.9	39
25	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	1.5	23
26	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	2.9	26
27	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	3.0	27
28	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.5	40
29	Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. <i>Arthritis Care and Research</i> , 2020, , .	1.5	8
30	Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2020, 11, 592639.	2.2	1
31	Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.	3.5	203
32	Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. <i>Lupus Science and Medicine</i> , 2020, 7, e000360.	1.1	14
33	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC€FI). <i>Arthritis Care and Research</i> , 2020, , .	1.5	9
34	Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1419-1433.	1.5	27
35	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	2.9	17
36	Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. <i>EClinicalMedicine</i> , 2020, 20, 100291.	3.2	47

#	ARTICLE	IF	CITATIONS
37	Low frequency of flares during pregnancy and post-partum in stable lupus patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 52.	1.6	37
38	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacept phase 2b ADDRESS II study. <i>Rheumatology</i> , 2020, 59, 2930-2938.	0.9	33
39	Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. <i>Lupus Science and Medicine</i> , 2020, 7, e000419.	1.1	6
40	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	1.5	70
41	Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REALâ„¢): a patient-reported outcome measure for lupus disease activity. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 99.	1.0	13
42	Immunologic findings precede rapid lupus flare after transient steroid therapy. <i>Scientific Reports</i> , 2019, 9, 8590.	1.6	14
43	Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. <i>Journal of Experimental Medicine</i> , 2019, 216, 1154-1169.	4.2	56
44	Measuring disease activity in SLE is an ongoing struggle. <i>Nature Reviews Rheumatology</i> , 2019, 15, 194-195.	3.5	15
45	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	2.9	25
46	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1125-1134.	2.9	74
47	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	0.9	8
48	98â€“Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAbâ„¢5871, in systemic lupus erythematosus (SLE). , 2019, , .		5
49	FRIO176â€“PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMABâ„¢5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). , 2019, , .		4
50	209â€“Attainment of low disease activity and remission with atacept in patients with systemic lupus erythematosus and high disease activity in the phase IIb ADDRESS II study and its long-term extension. , 2019, , .		0
51	21â€“Is lupus nephritis onset delayed in older caucasian females with less aggressive pathology?. , 2019, , .		0
52	233â€“Autoantibody-positive healthy individuals constrain T cell pathways to regulate autoimmune disease. , 2019, , .		0
53	296â€“Activated stress response genes and perturbation of regulatory pathways in anti-nuclear antibody positive individuals and SLE patients vary by cell type and race in single-cell transcriptomic analyses. , 2019, , .		0
54	SLE clinical trials: impact of missing data on estimating treatment effects. <i>Lupus Science and Medicine</i> , 2019, 6, e000348.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. <i>Lupus Science and Medicine</i> , 2019, 6, e000365.	1.1	23
56	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.5	12
57	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	2.9	55
58	Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 106-111.	0.4	11
59	Brief Report: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multiple-dose Study to Evaluate <sc>AMG</sc> 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1071-1076.	2.9	47
60	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	1.1	62
61	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , 2018, 27, 2392-2404.	1.4	34
62	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	0.9	37
63	Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 456-464.	1.0	13
64	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	1.5	55
65	New Trials in Lupus and where Are we Going. <i>Current Rheumatology Reports</i> , 2018, 20, 34.	2.1	10
66	Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 883-889.	0.5	107
67	Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 230-235.	1.5	41
68	Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. <i>Arthritis Care and Research</i> , 2018, 70, 1058-1063.	1.5	13
69	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018, 57, 125-133.	0.9	15
70	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 266-276.	2.9	184
71	CS-07...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
72	CT-06...Missing outcomes in SLE clinical trials: impact on estimating treatment effects. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000284.	1.1	51
74	Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. <i>Lupus Science and Medicine</i> , 2018, 5, e000266.	1.1	6
75	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , 2018, 27, 3813-3824.	1.4	43
76	Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2331.	1.8	12
77	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018, 5, e000263.	1.1	18
78	Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. <i>Arthritis Care and Research</i> , 2017, 69, 1780-1788.	1.5	34
79	Pathways of impending disease flare in African-American systemic lupus erythematosus patients. <i>Journal of Autoimmunity</i> , 2017, 78, 70-78.	3.0	33
80	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.5	111
81	The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 1257-1266.	2.9	36
82	Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. <i>Lupus Science and Medicine</i> , 2017, 4, e000176.	1.1	31
83	Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. <i>Clinical Immunology</i> , 2017, 185, 3-9.	1.4	18
84	Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. <i>Arthritis and Rheumatology</i> , 2017, 69, 785-790.	2.9	10
85	Editorial: Lupus, the Chameleon: Many Disguises Difficult to Capture. <i>Arthritis and Rheumatology</i> , 2017, 69, 1921-1924.	2.9	1
86	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
87	Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. <i>Lupus Science and Medicine</i> , 2017, 4, e000206.	1.1	11
88	Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. <i>Arthritis and Rheumatology</i> , 2017, 69, 643-654.	2.9	58
89	Anifrolumab, an Anti-Interferon- γ Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 376-386.	2.9	634
90	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	1.6	1

#	ARTICLE	IF	CITATIONS
91	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	2.9	114
92	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016, 7, 5.	2.2	30
93	Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. <i>Arthritis and Rheumatology</i> , 2016, 68, 1964-1969.	2.9	33
94	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	2.9	40
95	Sifalimumab, an anti-interferon- β monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1909-1916.	0.5	420
96	Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. <i>Arthritis and Rheumatology</i> , 2016, 68, 2492-2502.	2.9	79
97	Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. <i>Arthritis Research and Therapy</i> , 2016, 18, 197.	1.6	38
98	Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares. <i>Arthritis and Rheumatology</i> , 2016, 68, 2200-2209.	2.9	88
99	A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon- β) in patients with systemic lupus erythematosus (ROSE). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 196-202.	0.5	302
100	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2007-2013.	0.5	16
101	Why, why, why de-lupus (does so badly in clinical trials). <i>Expert Review of Clinical Immunology</i> , 2016, 12, 95-98.	1.3	22
102	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. <i>Lupus Science and Medicine</i> , 2016, 3, e000131.	1.1	118
103	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 242-252.	0.5	10
104	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	0.9	370
105	Differential Expression of the Transcription Factor ARID3a in Lupus Patient Hematopoietic Progenitor Cells. <i>Journal of Immunology</i> , 2015, 194, 940-949.	0.4	11
106	Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. <i>Lupus Science and Medicine</i> , 2015, 2, e000075-e000075.	1.1	26
107	A highlight from the LUPUS 2014 meeting: eight great ideas. <i>Lupus Science and Medicine</i> , 2015, 2, e000087.	1.1	12
108	Is SLE many single-organ diseases or an overlapping spectrum?. <i>Nature Reviews Rheumatology</i> , 2015, 11, 385-386.	3.5	9

#	ARTICLE	IF	CITATIONS
109	T Cell Targeted Therapies in Lupus: Do They Make Sense?. Current Treatment Options in Rheumatology, 2015, 1, 19-29.	0.6	0
110	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	2.9	98
111	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clinical Immunology, 2015, 161, 157-162.	1.4	10
112	Treatment of systemic lupus erythematosus patients with the BAFF antagonist α 1-1sibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Research and Therapy, 2015, 17, 215.	1.6	48
113	DNA methylation patterns in na \tilde{v} e CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus. Lupus Science and Medicine, 2015, 2, e000101.	1.1	83
114	Renal involvement in lupus is characterized by unique DNA methylation changes in na \tilde{v} e CD4+ T cells. Journal of Autoimmunity, 2015, 61, 29-35.	3.0	109
115	The IRF5 \hat{c} TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	1.4	74
116	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.5	70
117	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.5	391
118	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	1.1	4
119	Which outcome measures in SLE clinical trials best reflect medical judgment?. Lupus Science and Medicine, 2014, 1, e000005.	1.1	56
120	Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare. Arthritis and Rheumatology, 2014, 66, 1888-1899.	2.9	77
121	Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nature Reviews Rheumatology, 2014, 10, 23-34.	3.5	50
122	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2014, 41, 300-309.	1.0	149
123	A 2014 update on the management of patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2014, 44, e1-e2.	1.6	17
124	How should lupus flares be measured? Deconstruction of the Safety of Estrogen in Lupus Erythematosus National Assessment \hat{c} Systemic Lupus Erythematosus Disease Activity Index flare index. Rheumatology, 2014, 53, 2175-2181.	0.9	35
125	Systemic Lupus Erythematosus, Clinical Trials. , 2014, , 1156-1161.		0
126	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84

#	ARTICLE	IF	CITATIONS
127	Co-stimulatory molecules as targets for treatment of lupus. <i>Clinical Immunology</i> , 2013, 148, 369-375.	1.4	29
128	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.5	143
129	Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3364-3373.	6.7	100
130	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
131	Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 485-492.	6.7	53
132	Inhibitory Autoantibodies to Protein Disulfide Isomerase From Systemic Lupus Erythematosus Patients Are Prothrombotic. <i>Blood</i> , 2012, 120, 392-392.	0.6	0
133	Treatment of systemic lupus erythematosus: a 2012 update. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012, 70, 172-6.	0.7	11
134	Safety profile and clinical activity of sifalimumab, a fully human anti-interferon γ monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1905-1913.	0.5	205
135	The genetics of systemic lupus erythematosus and implications for targeted therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, i37-i43.	0.5	100
136	B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. <i>Arthritis and Rheumatism</i> , 2011, 63, 3931-3941.	6.7	59
137	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
138	Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1752-1757.	0.5	110
139	Ending the 50-year drought of FDA drug approval for SLE. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2011, 69, 238-42.	0.7	4
140	Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 222-233.	6.7	1,111
141	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.. <i>Blood</i> , 2010, 116, 3694-3694.	0.6	0
142	What does the death of Riquentâ„¢ hold for the future of SLE?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 306-307.	3.5	8
143	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
144	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1168-1178.	6.7	515

#	ARTICLE	IF	CITATIONS
145	What was wrong and might now go right with clinical trials for lupus?. <i>Current Rheumatology Reports</i> , 2009, 11, 235-237.	2.1	4
146	Chapter 14 Antiphospholipid Antibodies and Atherosclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 169-183.	0.1	0
147	Clinical trials for lupus--are we there yet?. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2009, 67, 267-70.	0.7	4
148	Is individualized medicine on the horizon for lupus?. <i>Current Rheumatology Reports</i> , 2008, 10, 257-258.	2.1	0
149	Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PTK, KIAA1542 and other loci. <i>Nature Genetics</i> , 2008, 40, 204-210.	9.4	1,192
150	Do antiphospholipid antibodies develop for a purpose?. <i>Current Rheumatology Reports</i> , 2006, 8, 109-113.	2.1	8
151	Antiphospholipid syndrome: What's new in understanding antiphospholipid antibody-related stroke?. <i>Current Rheumatology Reports</i> , 2006, 8, 159-161.	2.1	4
152	The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2005, 142, 953.	2.0	539
153	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2005, 353, 2550-2558.	13.9	962
154	Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2005, 353, 2219-2228.	13.9	991
155	Emergence of targeted immune therapies for systemic lupus. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 53-65.	1.0	2
156	Anti-β ₂ -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome. <i>American Journal of Clinical Pathology</i> , 2004, 121, 142-149.	0.4	86
157	Challenges in bringing the bench to bedside in drug development for sle. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 1036-1046.	21.5	35
158	Diagnosis of the antiphospholipid syndrome: How far to go?. <i>Current Rheumatology Reports</i> , 2004, 6, 469-472.	2.1	7
159	The antiphospholipid syndrome and atherosclerosis: Clue to pathogenesis. <i>Current Rheumatology Reports</i> , 2003, 5, 401-406.	2.1	11
160	Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1017-1025.	1.9	10
161	IgG Autoantibodies against β ₂ -Glycoprotein I Complexed with a Lipid Ligand Derived from Oxidized Low-Density Lipoprotein are Associated with Arterial Thrombosis in Antiphospholipid Syndrome. <i>Clinical and Developmental Immunology</i> , 2003, 10, 203-211.	3.3	52
162	Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. <i>Thrombosis and Haemostasis</i> , 2003, 90, 636-641.	1.8	40

#	ARTICLE	IF	CITATIONS
163	Regulation of the vasculature: clues from lupus. <i>Current Opinion in Rheumatology</i> , 2002, 14, 504-509.	2.0	4
164	Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 3251-3258.	6.7	321
165	A review of the obstetrics literature and the first novel treatment on the horizon. <i>Current Rheumatology Reports</i> , 2002, 4, 377-378.	2.1	0
166	Enhancement of Protein S Anticoagulant Function by Î²2-glycoprotein I, a Major Target Antigen of Antiphospholipid Antibodies:. <i>Thrombosis and Haemostasis</i> , 1999, 81, 748-757.	1.8	60
167	Selection of a gene for apolipoprotein a1 using autoantibodies from a patient with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1995, 38, 1655-1659.	6.7	25